ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs MXN
17.7398
0.22%
Brent Oil
84.34
-0.30%
Bitcoin
64,577.36
6.25%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Acceleron Pharma Inc (XLRN)

  7. Acceleron Pharma Inc (XLRN) Noticias

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
16/09/202006:00Business WireAcceleron Appoints Laura J. Hamill to its Board of DirectorsNASDAQ:XLRNAcceleron Pharma Inc
15/09/202015:51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
10/09/202009:04Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
06/08/202015:13Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
06/08/202015:10Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
06/08/202015:01Business WireAcceleron Reports Second Quarter 2020 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
06/08/202006:10Business WireAcceleron Announces Second Quarter 2020 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
27/07/202006:00Business WireAcceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020NASDAQ:XLRNAcceleron Pharma Inc
16/07/202016:01Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:XLRNAcceleron Pharma Inc
07/07/202015:04Business WireAcceleron Announces Closing of Public Offering of Common Stock & Exercise of Underwriters’ Option to Purchase Additional Sh...NASDAQ:XLRNAcceleron Pharma Inc
06/07/202016:23Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
30/06/202017:48Business WireAcceleron Announces Pricing of Public Offering of Common StockNASDAQ:XLRNAcceleron Pharma Inc
30/06/202005:45Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:XLRNAcceleron Pharma Inc
29/06/202015:01Business WireAcceleron Announces Proposed Public Offering of Common StockNASDAQ:XLRNAcceleron Pharma Inc
26/06/202008:53Dow Jones NewsBristol-Myers, Acceleron Get EU Approval for ReblozylNASDAQ:XLRNAcceleron Pharma Inc
26/06/202008:05Business WireEuropean Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with...NASDAQ:XLRNAcceleron Pharma Inc
24/06/202014:15Business WireAcceleron Presents Topline Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
22/06/202006:00Business WireAcceleron to Host Conference Call & Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Th...NASDAQ:XLRNAcceleron Pharma Inc
04/06/202015:05Business WireAcceleron Appoints Christopher Hite to its Board of DirectorsNASDAQ:XLRNAcceleron Pharma Inc
20/05/202006:00Business WireAcceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2020 American Society of Clinical Oncology & Europ...NASDAQ:XLRNAcceleron Pharma Inc
19/05/202006:00Business WireAcceleron Announces Oral Presentation of PULSAR Phase 2 Trial Results in Virtual American Thoracic Society 2020 Conference Se...NASDAQ:XLRNAcceleron Pharma Inc
13/05/202015:01Business WireAcceleron Announces Publication in Science Translational Medicine Describing the Underlying Biology Behind Sotatercept’s Po...NASDAQ:XLRNAcceleron Pharma Inc
11/05/202015:05Business WireAcceleron Reports First Quarter 2020 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
05/05/202006:00Business WireAcceleron to Webcast First Quarter 2020 Operating and Financial Results on May 11, 2020NASDAQ:XLRNAcceleron Pharma Inc
04/05/202006:00Business WireAcceleron Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Sotatercept in Pulmonary A...NASDAQ:XLRNAcceleron Pharma Inc
30/04/202016:15Dow Jones NewsBristol Myers, Acceleron Pharma's Anemia Treatment Gets Nod From European RegulatorNASDAQ:XLRNAcceleron Pharma Inc
30/04/202015:16Business WireReblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia & Myelodys...NASDAQ:XLRNAcceleron Pharma Inc
16/04/202015:36Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XLRNAcceleron Pharma Inc
16/04/202015:34Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XLRNAcceleron Pharma Inc
08/04/202006:05Business WireAcceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN

Su Consulta Reciente

COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
CCOM
US30
US 30
NASDAQ
GOOGL
Alphabet
FX
USDMXN
US Dollar vs MXN
NYSE
MCD
McDonalds
NYSE
VZ
Verizon Communications
NASDAQ
AMZN
Amazon.com
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
FX
EURUSD
Euro vs US Dollar
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados